Diabetes, weight loss drug companies growth far from over, says ClearBridge analyst

ClearBridge research analyst Marshall Gordon sits down with InvestmentNews anchor Gregg Greenberg to discuss the rise of new diabetes and weight-loss drugs, as well as the best ways to invest in this burgeoning sector.
  • Aug 30, 2023
More: IN THE NASDAQ
Ed Slott offers end-of-year tax-planning, retirement moves

Ed Slott offers end-of-year tax-planning, retirement moves

Best bond moves to make before the end of 2024

Best bond moves to make before the end of 2024

What’s keeping wealthy families up at night?

What’s keeping wealthy families up at night?